- Home
- About Us
- Products & Services
- Our Services
- License Representative
- Product Registration
- Medical Device Company Establishment Service
- Renewal and License Amendment
- Miscellaneous Certificates
- Post-Marketing Surveillance
- E- Catalogue
- Medical Device Trademark Management
- CDAKB (Good Distribution Practice for Medical Device)
- Regulatory Intelligence
- research material products
- Our Services
- Articel
- Asia Regulatory Information
- Our Clients
- Gallery
- Contact US

The Indonesian Ministry of Health (MoH) has officially announced, under number FR.03.01/E.V/2672/2024, that Dried Blood Spot (DBS) is now classified as an In Vitro Diagnostic (IVD) medical device. This classification aligns with regulation PMK 62/2017 and references the Code of Federal Regulations (CFR) Title 21 from the U.S. Food and Drug Administration (FDA).
Dried Blood Spot is a method used to collect, dry, store, and transport whole blood samples to laboratories for newborn screening (NBS). This technique is crucial for the early detection of various health conditions in newborns, significantly contributing to improved healthcare outcomes.
For information regarding new registrations, changes, and extensions of your medical device and IVD device, please contact us.
Artikel Lainnya
-
Indonesia's Ministry of Health Recognizes Dried Blood Spot as IVD Medical Device
-
GDPMD and Impact on Medical Device Registration in Indonesia
-
Transition from Waarmerking to Notarial Deed: New Agreement Validation for PJT and Companies in Medical Device Distribution
-
Understanding GB 9706.1-2020: The Chinese Standard Equivalent to IEC 60601.1 Part 1
-
Indonesia Ministry of Health Mandates GDPMD Certification for E-Catalogue Enrolment in 2025